We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
United Airlines
UAL
$39.4B
| $1.57M | 0.18% |
37,031
+11,847
| +47% | +$599K |
|
152
Rollins
ROL
$18.3B
| $1.56M | 0.18% |
41,811
+23,176
| +124% | +$936K |
|
153
Inspire Medical Systems
INSP
$1.45B
| $1.56M | 0.18% |
+7,850
| New | +$1.98M |
|
154
NRG Energy
NRG
$28.3B
| $1.55M | 0.18% |
40,324
-60,988
| -60% | -$2.31M |
|
155
Corebridge Financial
CRBG
$14.1B
| $1.5M | 0.18% |
75,850
+25,566
| +51% | +$476K |
|
156
Allstate
ALL
$68B
| $1.47M | 0.17% |
+13,208
| New | +$1.44M |
|
|
CUK
157
DELISTED
Carnival PLC
CUK
| $1.47M | 0.17% |
119,975
+75,537
| +170% | +$1.13M |
|
158
Iovance Biotherapeutics
IOVA
$1.82B
| $1.45M | 0.17% |
319,502
+187,253
| +142% | +$1.22M |
|
159
PTC Therapeutics
PTCT
$5.68B
| $1.45M | 0.17% |
+64,722
| New | +$2.41M |
|
160
Tenet Healthcare
THC
$20.5B
| $1.44M | 0.17% |
21,859
+13,387
| +158% | +$1M |
|
161
Chegg
CHGG
$110M
| $1.43M | 0.17% |
160,733
-103,607
| -39% | -$1.01M |
|
|
NOVA
162
DELISTED
Sunnova Energy
NOVA
| $1.42M | 0.17% |
135,560
-31,924
| -19% | -$499K |
|
163
Travel + Leisure Co
TNL
$4.66B
| $1.42M | 0.17% |
+38,578
| New | +$1.54M |
|
164
MarketAxess Holdings
MKTX
$5.71B
| $1.41M | 0.17% |
6,604
+5,017
| +316% | +$1.22M |
|
165
Motorola Solutions
MSI
$72.3B
| $1.4M | 0.16% |
5,155
+3,271
| +174% | +$932K |
|
166
BHP
BHP
$215B
| $1.4M | 0.16% |
+24,597
| New | +$1.44M |
|
167
O-I Glass
OI
$1.1B
| $1.39M | 0.16% |
83,312
+73,735
| +770% | +$1.48M |
|
168
Cardinal Health
CAH
$53.9B
| $1.39M | 0.16% |
16,050
-9,803
| -38% | -$886K |
|
169
Clorox
CLX
$11.6B
| $1.37M | 0.16% |
10,488
+4,503
| +75% | +$684K |
|
170
Service Corp International
SCI
$11.7B
| $1.36M | 0.16% |
+23,784
| New | +$1.5M |
|
171
Lockheed Martin
LMT
$134B
| $1.35M | 0.16% |
+3,309
| New | +$1.47M |
|
172
HSBC
HSBC
$365B
| $1.35M | 0.16% |
+34,231
| New | +$1.35M |
|
173
CSX Corp
CSX
$93.4B
| $1.35M | 0.16% |
+43,830
| New | +$1.39M |
|
174
Insmed
INSM
$21.4B
| $1.31M | 0.15% |
+52,051
| New | +$1.19M |
|
175
Pultegroup
PHM
$24.1B
| $1.31M | 0.15% |
+17,724
| New | +$1.41M |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.